申请人:Pierre Fabre Medicament
公开号:US07109234B2
公开(公告)日:2006-09-19
The invention concerns 3-arylthio-propyl-amino-3,4-dihydro-2H-1,5-aryloxathiepin derivatives of general formula (I), wherein: R1 and R2, identical or different, represent a hydrogen atom, a fluorine atom or a chlorine atom, a hydroxy group, an alkyl, cyclopropyl, alkoxy, cyclopropoxy radical or when they occupy adjacent positions, form with the carbon atoms bearing them a carbon-containing cycle or an oxygen-containing heterocycle with five non-aromatic rings; R3 represents an alkyl radical, a hydroxy group or a methoxy radical; R4 represents a hydrogen atom or a methyl radical; and R5 and R6, identical or different represent a hydrogen atom, an alkyl, alkoxy, alkylthio, alkylamino radical, or the groups OR4 and R5 form with the carbons which bear them a non-aromatic heterocycle with five or six rings containing at least an oxygen atom; and their pharmaceutically acceptable additions salts
本发明涉及一般式(I)的3-芳基硫代丙基氨基-3,4-二氢-2H-1,5-芳氧硫杂环戊烷衍生物,其中:R1和R2,相同或不同,代表氢原子,氟原子或氯原子,羟基,烷基,环丙基,烷氧基,环丙氧基基团,或当它们占据相邻位置时,与它们相连的碳原子形成含有五个非芳香环的碳含环或含有五个非芳香环的氧杂环;R3代表烷基基团,羟基或甲氧基基团;R4代表氢原子或甲基基团;R5和R6,相同或不同,代表氢原子,烷基,烷氧基,烷硫基,烷基氨基基团,或OR4和R5与它们所带的碳原子形成含有至少一个氧原子的五环或六环非芳香杂环;以及它们的药学上可接受的加盐酸盐。